EPHA2 and non-small cell lung carcinoma: Iyer et al. generated dual-stimuli nanoparticles (E-DSNPs) loaded with cisplatin and a radiation sensitizer and functionalized with anti-EPHA2 antibodies, which selectively targeted EPHA2-expressing NSCLC cells.